- Home
- GLDD vs NUVB Comparison
GLDD vs NUVB Comparison
Compare GLDD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDD
- NUVB
- Stock Information
- Founded
- GLDD 1890
- NUVB 2018
- Country
- GLDD United States
- NUVB United States
- Employees
- GLDD N/A
- NUVB N/A
- Industry
- GLDD Military/Government/Technical
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- GLDD Industrials
- NUVB Health Care
- Exchange
- GLDD Nasdaq
- NUVB Nasdaq
- Market Cap
- GLDD 829.6M
- NUVB 959.2M
- IPO Year
- GLDD 2006
- NUVB N/A
- Fundamental
- Price
- GLDD $11.64
- NUVB $2.82
- Analyst Decision
- GLDD Buy
- NUVB Strong Buy
- Analyst Count
- GLDD 1
- NUVB 6
- Target Price
- GLDD $14.00
- NUVB $6.33
- AVG Volume (30 Days)
- GLDD 408.4K
- NUVB 2.5M
- Earning Date
- GLDD 02-12-2025
- NUVB 11-06-2024
- Dividend Yield
- GLDD N/A
- NUVB N/A
- EPS Growth
- GLDD N/A
- NUVB N/A
- EPS
- GLDD 0.87
- NUVB N/A
- Revenue
- GLDD $741,648,000.00
- NUVB $2,162,000.00
- Revenue This Year
- GLDD $33.01
- NUVB N/A
- Revenue Next Year
- GLDD $6.88
- NUVB N/A
- P/E Ratio
- GLDD $13.34
- NUVB N/A
- Revenue Growth
- GLDD 33.74
- NUVB N/A
- 52 Week Low
- GLDD $6.55
- NUVB $1.43
- 52 Week High
- GLDD $12.89
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- GLDD 40.95
- NUVB 55.36
- Support Level
- GLDD $11.30
- NUVB $2.51
- Resistance Level
- GLDD $11.97
- NUVB $2.87
- Average True Range (ATR)
- GLDD 0.41
- NUVB 0.18
- MACD
- GLDD -0.12
- NUVB -0.01
- Stochastic Oscillator
- GLDD 21.38
- NUVB 64.58
About GLDD Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).